Introduction:
Nitrosamine sample preparation and extraction is the single most consequential step in generating defensible, low-level impurity data — get it wrong, and even the best mass spectrometer will report misleading results. Since the global nitrosamine crisis began with contamination findings in sartans, ranitidine, and metformin, regulatory agencies have pushed detection limits into the low parts-per-billion and even parts-per-trillion range. At these concentrations, extraction technique is not a procedural afterthought; it is often the difference between a passing lot release and a false-positive investigation that consumes weeks of laboratory and regulatory resources.
This article breaks down the three extraction approaches used most often in pharmaceutical nitrosamine testing — SPE, LLE, and headspace analysis — and explains when each is appropriate, what can go wrong, and how a CRO/CDMO builds a defensible method around them as part of building a nitrosamine testing program from scratch.
Summary:
- Nitrosamine sample preparation directly determines whether trace-level (ppb/ppt) impurities are detected reliably, since these compounds are reactive, thermally sensitive, and prone to artifactual formation during extraction
- Solid Phase Extraction (SPE) is the workhorse for solid oral dosage forms and offers the best cleanup for complex matrices
- Liquid-Liquid Extraction (LLE) remains valuable for simple matrices and specific volatile nitrosamines but carries higher risk of emulsion and recovery variability
- Headspace methods are essential for volatile nitrosamines (e.g., NDMA, NDEA) and avoid matrix interference entirely by sampling only the vapor phase
- Method selection depends on the API, matrix complexity, target nitrosamine volatility, and required limit of quantitation (LOQ) relative to the Acceptable Intake (AI)
- Regulatory bodies (FDA, EMA, Health Canada) expect method-specific justification for extraction technique choice as part of nitrosamine control strategies
1: Why Sample Preparation Is the Critical Control Point for Nitrosamine Analysis
Poor sample preparation is the leading cause of both false negatives (missed contamination) and false positives (artifactual nitrosamine formation) in impurity testing. Nitrosamines can form during sample handling itself if secondary or tertiary amines in the formulation come into contact with nitrite sources — including residual nitrite in excipients, nitrogen oxides from ambient air, or even acidic conditions during extraction.
Key risk factors that extraction method choice must control for:
- In-situ nitrosamine formation — acidic extraction conditions combined with amine-nitrite proximity can generate artifacts
- Volatility losses — low-molecular-weight nitrosamines (NDMA, NDEA) can evaporate during open-vessel extraction or evaporative concentration steps
- Matrix interference — excipients, polymers, and formulation components can suppress or enhance MS ionization if not adequately removed
- Recovery inconsistency — inadequate extraction efficiency across a spiked recovery range undermines quantitation accuracy near the LOQ
These same risk factors are why a rigorous, upfront nitrosamine risk assessment for combination oral solid dosage forms is often the starting point before any extraction method is even selected.
2: Solid Phase Extraction (SPE) for Nitrosamine Sample Preparation and Extraction
SPE answers the question of selective cleanup best: it isolates nitrosamines from complex solid-dosage matrices using a sorbent cartridge, delivering cleaner extracts and better chromatographic performance than direct-inject or simple LLE approaches.
SPE works by passing a dissolved or extracted sample through a cartridge packed with a selective sorbent (commonly C18, HLB, or mixed-mode phases), which retains nitrosamines while polar or non-polar interferents pass through or are washed off, followed by selective elution.
Typical SPE workflow for nitrosamine analysis:
| Step | Purpose |
|---|---|
| Sample dissolution/extraction | Solubilize API and release nitrosamines into extraction solvent |
| Cartridge conditioning | Activate sorbent phase with solvent/water |
| Sample loading | Retain nitrosamines on the sorbent |
| Wash step | Remove co-extracted matrix interferents |
| Elution | Selectively release nitrosamines into a small solvent volume |
| Concentration (if needed) | Achieve required sensitivity for GC-MS/MS or LC-MS/MS |
Advantages:
- Excellent matrix cleanup, reducing ion suppression in MS detection
- High concentration factors achievable, supporting sub-ppb LOQs
- Reproducible and automatable for high-throughput testing programs
- Well suited to solid oral dosage forms, APIs, and complex excipient blends
Limitations:
- Method development is more time-intensive than LLE
- Sorbent selection must be validated per nitrosamine class (volatile vs. non-volatile, N-nitroso amino acids, etc.)
- Cartridge lot-to-lot variability requires monitoring
SPE cleanup is particularly important for complex molecules — for example, a nitrosamine risk assessment for peptide APIs often requires sorbent selection tailored to peptide-associated secondary amine chemistry, where generic C18 phases may not deliver adequate selectivity.
3: Liquid-Liquid Extraction (LLE) for Nitrosamine Sample Preparation and Extraction
LLE answers the simplicity question directly: it is the fastest, lowest-cost extraction option for simpler matrices, using differential solubility between an aqueous phase and an immiscible organic solvent to partition nitrosamines out of the sample.
In practice, the sample is dissolved in an aqueous buffer, then partitioned against dichloromethane, ethyl acetate, or similar solvents. Repeated extractions improve recovery, and the combined organic layer is concentrated prior to instrumental analysis.
When LLE is the right choice:
- Simple matrices with minimal excipient interference (e.g., certain APIs, water-soluble drug substances)
- Screening-level or early-development testing where full SPE method development isn’t yet justified
- Nitrosamines with favorable partition coefficients into common extraction solvents
Known challenges with LLE:
- Emulsion formation with surfactant-containing formulations, complicating phase separation
- Solvent evaporation steps risk losing volatile nitrosamines before detection
- Generally lower selectivity than SPE, increasing background interference
- Larger solvent volumes raise both cost and environmental/safety handling burden
This trade-off between simplicity and selectivity is a recurring theme in drug-class-specific work — a nitrosamine risk assessment for a proton pump inhibitor, for instance, often starts with LLE screening before moving to SPE-based confirmatory methods once impurity hotspots are identified.
4: Headspace Methods for Volatile Nitrosamine Analysis
Headspace analysis answers the volatility problem directly: rather than extracting nitrosamines into a liquid phase, it equilibrates the sample in a sealed vial and samples only the vapor above it — avoiding matrix contact with the detector entirely and minimizing degradation risk for the most volatile nitrosamine species.
This is the preferred approach for NDMA, NDEA, NDIPA, NEIPA, and similar low-boiling-point nitrosamines, which are notoriously prone to loss during solvent evaporation or open-vessel handling in SPE/LLE workflows.
Static vs. dynamic headspace:
| Parameter | Static Headspace | Dynamic Headspace / Purge-and-Trap |
|---|---|---|
| Sensitivity | Moderate | High (trapped analyte, larger effective sample) |
| Matrix interference | Very low | Low |
| Equipment complexity | Simple, widely available | Higher (trap, thermal desorption) |
| Best for | Routine volatile nitrosamine screening | Ultra-trace quantitation near regulatory AI limits |
Advantages of headspace for nitrosamine testing:
- No solvent extraction artifacts or evaporative losses
- Minimal matrix background, simplifying GC-MS/MS quantitation
- Reduced risk of in-situ nitrosamine formation from extraction chemistry
- Directly compatible with regulatory expectations for volatile NDSRI (nitrosamine drug substance-related impurity) testing
Limitations:
- Not applicable to non-volatile or high-molecular-weight nitrosamines
- Requires careful method optimization (equilibration temperature/time, salt addition) to maximize sensitivity
Volatility isn’t only a drug-substance concern — packaging and container-closure systems can also introduce volatile nitrosamine risk, which is why nitrosamine leachables testing frequently relies on the same headspace principles described here.
5: Choosing the Right Extraction Technique: A Comparative Framework
| Factor | SPE | LLE | Headspace |
|---|---|---|---|
| Matrix complexity handled | High | Low–Moderate | Any (vapor sampling only) |
| Best for volatile nitrosamines | Moderate | Moderate–Poor | Excellent |
| Sensitivity achievable | Very high | Moderate | High |
| Method development effort | Higher | Lower | Moderate |
| Risk of artifact formation | Low (controlled conditions) | Moderate | Very low |
| Typical instrumentation pairing | LC-MS/MS, GC-MS/MS | GC-MS/MS | GC-MS/MS (headspace-GC) |
In practice, many nitrosamine control strategies use more than one technique — headspace for volatile species alongside SPE or LC-MS/MS-based methods for non-volatile NDSRIs — to provide comprehensive coverage across a compound’s full nitrosamine risk profile. This layered approach is especially critical for large-molecule products, where a nitrosamine compliance strategy for biosimilars must account for both formulation-derived and process-derived nitrosamine sources.
Regulatory Expectations Around Extraction Method Selection
FDA, EMA, and Health Canada guidance on nitrosamine impurities all emphasize that extraction and sample preparation methods must be scientifically justified and validated to demonstrate adequate recovery, specificity, and sensitivity at or below the compound-specific Acceptable Intake. Regulators increasingly expect sponsors to document why a particular extraction technique was chosen relative to the physicochemical properties of the target nitrosamine — volatility, polarity, and matrix behavior — rather than defaulting to a single generic method across an entire product portfolio.
This is where experienced analytical partners add real value: matching extraction chemistry to the specific nitrosamine risk profile of a formulation, rather than applying a one-size-fits-all protocol.
Conclusion:
Reliable nitrosamine sample preparation and extraction is not a single fixed protocol — it is a matrix- and compound-specific decision between SPE, LLE, and headspace methods, each with distinct strengths for cleanup, sensitivity, and volatility handling. Getting this step right is foundational to generating trustworthy, regulator-ready nitrosamine impurity data, particularly as acceptable intake limits continue to tighten across global markets.
Frequently Asked Questions:
LLE can involve relatively high solvent consumption and greater manual handling than some SPE procedures.
Emulsion formation and incomplete phase separation can affect extraction reproducibility.
Analyte loss can also occur during transfers, evaporation, or inappropriate solvent selection.
These factors should be evaluated during recovery and precision studies.
Headspace extraction is particularly useful for volatile or semi-volatile nitrosamines analyzed using GC-based techniques.
The sample is placed in a sealed vial and allowed to establish equilibrium between the sample and gas phase.
An aliquot of the headspace is then introduced into the GC system.
This approach can reduce the amount of nonvolatile pharmaceutical matrix entering the instrument.
Matrix components can alter analyte ionization during LC-MS analysis, causing ion suppression or ion enhancement.
This can change the measured response and potentially affect quantitative accuracy.
Complex APIs, excipients, and formulation components can contribute to matrix effects.
Extraction cleanup, dilution, chromatographic separation, and suitable internal standards can help control them.
Yes, nitrosamines can potentially be lost through incomplete extraction, adsorption, evaporation, degradation, or inappropriate filtration.
Multiple sample-transfer steps can also introduce variability or loss.
Recovery studies at relevant concentration levels help identify these problems.
Sample preparation should therefore be optimized together with the instrumental method.
Reference
- Tarafder A, Vega E, Beck HP, Mundal D, Tilala M, Wang S. Nitrosamine control: from risk assessment to analytical testing with emphasis on sample preparation and phase-appropriate method validation. Organic Process Research & Development. 2025 Nov 7;29(11):2602-24.https://pubs.acs.org/doi/abs/10.1021/acs.oprd.5c00158
- Shaik KM, Sarmah B, Wadekar GS, Kumar P. Regulatory updates and analytical methodologies for nitrosamine impurities detection in sartans, ranitidine, nizatidine, and metformin along with sample preparation techniques. Critical reviews in analytical chemistry. 2022 Jan 2;52(1):53-71.https://www.tandfonline.com/doi/abs/10.1080/10408347.2020.1788375
- Alsayadi YM, Dogra R, Arora V, Shiven A. Innovations in the detection of N-nitrosamine impurities in pharmaceuticals: analytical and regulatory challenges. Critical Reviews in Analytical Chemistry. 2025 May 31:1-26.https://www.tandfonline.com/doi/abs/10.1080/10408347.2025.2512443
- Ramezani H, Hosseini H, Kamankesh M, Ghasemzadeh-Mohammadi V, Mohammadi A. Rapid determination of nitrosamines in sausage and salami using microwave-assisted extraction and dispersive liquid–liquid microextraction followed by gas chromatography–mass spectrometry. European Food Research and Technology. 2015 Feb;240(2):441-50.https://link.springer.com/article/10.1007/s00217-014-2343-4
About the Author
